Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Eligibility And Liability topic
No spam. Unsubscribe anytime.
Conferees debate supervision, federal‑wide assurance and immunity language in HB701‑FN
Summary
Committee conferees examined whether HB 701‑FN should permit experimental treatments at satellite sites under a parent facility’s federal wide assurance, how to define “direct supervision,” and whether immunity should cover “reckless” as well as “willful” misconduct.
Committee conferees on HB 701‑FN spent an extended portion of the conference discussing who may lawfully administer certain experimental medical treatments and the statutory protections and administrative requirements for eligible facilities.
Representative Leon and several senators and house conferees debated three interlinked points: (1) whether a facility in New Hampshire may rely on a federal wide assurance (FWA) held by a parent institution in another state or by a satellite location; (2) what “direct supervision” by an eligible facility requires in practice; and (3) whether the bill’s civil immunity should include “reckless” conduct in addition to “willful misconduct.”
Several conferees said obtaining an FWA can take weeks to months and, in some cases, longer than a patient’s clinical window, which would create access barriers if the statute required the FWA at every physical satellite site. Representative Leon proposed language to recognize a licensed New Hampshire institution operating under an FWA or a satellite location of an institution licensed in another state that operates under that FWA. Senator Abbas and others expressed concern about potential federal compliance issues but did not object to drafting that would explicitly include satellite locations for clarity.
Conferees sought a practical definition of “direct supervision.” One attendee said direct supervision would indicate a medical staff member from the parent organization is physically present at the eligible facility during administration; others noted that embedding detailed operational supervision requirements in statute may be less workable than delegating limits and definitions to administrative rules. The group discussed using rulemaking to define supervision so the Department and licensing boards could adjust specifics over time.
On immunity, conferees agreed to consider adding “reckless” alongside “willful” to limit the statutory immunity so it did not bar claims for grossly unreasonable conduct. A New Hampshire Supreme Court definition of reckless conduct was cited in committee discussion as a possible guide. Conferees also discussed patient eligibility and cross‑state continuity of care when patients travel to New Hampshire for treatment; members emphasized such care is typically collaborative among multiple providers rather than a simple discharge and transfer.
No formal committee vote was recorded on these points during the session. The conferees recessed and scheduled another meeting at 10:30 a.m. the next day to finalize draft language with OLS and to determine whether to add “reckless” to the immunity provision and to clarify eligible‑facility language.
The debate highlighted practical tradeoffs: protecting patients and complying with federal research protections, limiting legal exposure for providers, and ensuring rules are implementable by hospitals and clinics without creating barriers that would effectively block access.
